Takeda signed a multiyear R&D collaboration with San Diego AI biotech Iambic to apply generative and predictive models to small‑molecule programs across oncology, gastrointestinal, and inflammation targets. Takeda framed the deal as part of a broader AI integration strategy to accelerate discovery and target selection. Takeda research chief Andy Plump emphasized that companies that fully embed AI into drug development will lead future innovation. The partnership combines Takeda’s therapeutic expertise with Iambic’s computational platform and will include undisclosed targets and milestone‑based development plans.